The efficacy and safety of tigecycline for the treatment of complicated intra-adominal infections - The European experience

Journal of Chemotherapy

Volumn 20, Issue SUPPL. 1, 2008, Pages 12-19

  Fomin, Peter ^a   Koalov, S ^a   Cooper, A ^b   Babinchak, T ^b   Dartois, N ^c   De Vane, N ^c   Castaing, N ^c   Tellado, J ^d  

^a BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b PFIZER INC   (United States)

^c Neuroscience Department   (France)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

ClinicalTrials.gov identifier: NCT00081744 and NCT00136201; Efficacy; Imipenem cilastatin; Intra abdominal infections; Safety; Tigecycline

Indexed keywords

CILASTATIN PLUS IMIPENEM; TIGECYCLINE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ADULT; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APPENDICITIS; ARTICLE; BACTERIUM ISOLATE; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; HYPERAMYLASEMIA; HYPERGLYCEMIA; IN VITRO STUDY; INFECTION; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTHEMIA; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 57749083229     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.supplement-1.12     Document Type: Article

References (31)

1. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005; 65: 1611-1620.
2. Sweet RL, Bartlett JG, Hemsell DL et al. Evaluation of new anti-infective drugs for the treatment of acute pelvic inflammatory disease. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15, Suppl 1: S53-61.
3. Solomkin J, Mazuski J, Baron Eea. Guidelines for the Selection of Anti-infective Agent for Complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
4. Woodford N, Ward ME, Kaufmann ME. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-743.
5. Rossi F, Baquero F, Hsueh PR et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58: 205-210.
6. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-454.
7. Munday CJ, Whitehead GM, Todd NJ et al. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628-633.
8. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
9. Gales AC, Silva JB, Andrade SS et al. In vitro activity of the tigecycline, a new glycylcycline, tested against 1326 clinical bacterial strains isolated from the Latin American region. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003; 43: 207.
10. Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595-2601.
11. Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43, 738-744.
12. Bush K, Macielag M. New approaches in the treatment of bacterial infections. Curr Opin Chem Biol 2000; 4: 433-439.
13. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: Getting it right the first time. Drugs 2003; 63: 2157-2168.
14. Meehan TP, Fine MJ, Krumholz HM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-2084.
15. Mylotte JM, Graham R, Kahler L et al. Epidemiology of nosocomial infection and resistant organisms in patients admitted for the first time to an acute rehabilitation unit. Clin Infect Dis 2000; 30: 425-432.
16. Shlaes DM, Gerding DN, John JFJ. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Clin Infect Dis 1997; 25: 584-599.
17. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
18. Hurr H, Hawley HB, Czachor JS et al. APACHE II and ISS scores as predictors of nosocomial infections in trauma patients. Am J Infect Contr 1999; 27: 79-83.
19. McCusker ME, Perisse AR, Roghmann MC. Severity-of-illness markers as predictors of nosocomial infection in adult intensive care unit patients. Am J Infect Control 2002; 30: 139-144.
20. Craven DE, Kunches LM, Lichtenberg DA et al. Nosocomial infection and fatality in medical and surgical intensive care unit patients. Arch Intern Med 1988; 148: 1161-1168.
21. Cunnion KM, Weber DJ, Broadhead WE et al. Risk factors for nosocomial pneumonia: comparing adult critical-care populations. Am J Respir Crit Care Med 1996; 153: 158-162.
22. Mazuski J, Sawyer R, Nathens Aea. The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: An Executive Summary. Surg Infect 2002; 3: 161-173.
23. Oliva ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
24. Fomin P, Beuran M, Gradauskas A et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3: 35-47.
25. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40: 173-177.
26. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-487.
27. Krobot K, Yin D, Zhang Q et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23: 682-687.
28. Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400-404.
29. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003; 31: 2228-2237.
30. Mazuski JE. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 2007; 8: 2933-2945.
31. Laterre PF, Colardyn F, Delmee M et al. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB). Acta Chir Belg 2006; 106: 2-21.